Case report

A case of Cryptococcus gattii infection in South Carolina: A possible challenge to known endemicity

Robert P. Summers\textsuperscript{a,}\textsuperscript{*}, William F. Abel\textsuperscript{a,}\textsuperscript{*}, William S. Sessions\textsuperscript{b}, Eric M. Polley\textsuperscript{b}, Rhett M. Shirley\textsuperscript{c}, Amanda E. Schnee\textsuperscript{c}

\textsuperscript{a} University of South Carolina School of Medicine Greenville, 607 Grove Rd., Greenville, SC 29605, United States
\textsuperscript{b} Prisma Health System Department of Internal Medicine, 701 Grove Rd., Greenville, SC 29605, United States
\textsuperscript{c} Prisma Health System Department of Infectious Disease, 701 Grove Rd., Greenville, SC 29605, United States

\begin{abstract}
In the United States, C. gattii is considered to be endemic to the Pacific Northwest and although uncommon, additional cases have been documented in other regions including the Southeastern United States. While it has been hypothesized in the past that C. gattii may be endemic to the Southeastern United States, there remains a paucity of evidence. Here, we present a patient with no history of HIV/AIDS and no organ transplant and document the course of his disease and presentation. There were no adverse long-term neurological outcomes in this patient and the combination of steroid use, antifungal agents, and cerebrospinal fluid drainage resulted in his discharge from the hospital after 12 days. This patient’s subacute presentation with vague neurological symptoms highlights the importance of understanding the treatment of rare causes of meningitis.

\copyright\ 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
\end{abstract}

Background

Cryptococcosis in the United States is usually attributed to Cryptococcus neoformans in immunocompromised patients, such as patients with HIV/AIDS, patients receiving immunosuppressive drugs like chemotherapy, or patients who have received solid organ transplant [1]. However, in recent years, there have been cases where species of the recently revised Cryptococcus species complexes, such as C. gattii and C. deuterogattii, have been attributed to illness in immunocompetent patients [1].

C. neofor\textit{m}ans is a largely opportunistic pathogen that is particularly devastating in the demographic encompassing patients with AIDS and conditions leading to immunocompromise [2]. A number of virulence factors have been identified in C. neofor\textit{m}ans including rim101 which has a role in inducing inflammation as well as inducing adaptations to pH changes [3]. C. neofor\textit{m}ans has been shown to have a higher susceptibility to antifungal azole agents than C. gattii and C. neo\textit{f}or\textit{m}ans.\textsuperscript{a}

C. deuterogattii has been isolated in Australia, as well as Denmark, Germany, and Japan, with an increase in the number of cases reported after international travel [5]. Across the species complex, C. deuterogattii possesses the largest cell size and the greatest tolerance to high-heat conditions [6]. Additionally, C. deuterogattii has been shown to have the least susceptible of cryptococcus species to antifungal azoles [4].

C. gattii, is considered to be endemic to a number of regions throughout the world including the Pacific Northwest of the United States, parts of South America, Oceana, and possibly the Southeastern United States [7]. It shares many virulence factors with C. neo\textit{f}or\textit{m}ans, including the same polysaccharide capsule structure and superoxide dismutase [1]. Most cases have involved immunocompetent patients with a history of travel to an endemic region [1].

Infection with Cryptococcal spores occurs by inhalation [8]. Symptoms can vary with the severity of infection from asymptomatic to pneumonia, as well as infection of the eyes, the skin, and the CNS causing meningitis and meningoencephalitis [8]. A protease produced by C. gattii allows for the formation of large inflammatory Cryptococcosas that could potentially require long-term treatment with antifungal therapy and even neurological intervention [9].

Treatment options vary depending on the patient and are divided into three subgroups: HIV patients, organ transplant patients, and non-HIV/non-transplant patients [10]. Various

\textsuperscript{a} Corresponding authors.
\textsuperscript{b} E-mail addresses: summersp@email.sc.edu (R.P. Summers), wabel@email.sc.edu (W.F. Abel).

Abbreviations: HIV/AIDS, Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome; U.S., United States; CDC, Centers for Disease Control; COPD, Chronic Obstructive Pulmonary Disease; GERD, Gastroesophageal Reflux Disease; RPR, Rapid Plasma Reagin; mg, milligrams; Kg, kilogram; IV, Intravenous.

\textsuperscript{*} Corresponding authors.

http://dx.doi.org/10.1016/j.idcr.2020.e01027
2214–2509/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
combinations and formulations of amphotericin B, fluconazole, and fluocytosine are the most commonly used medications based on these subgroups in order to achieve appropriate therapy during induction, consolidation, and maintenance [10,11].

C. gattii infections have been documented throughout the world in diverse locations including Thailand, Australia, Papua New Guinea, the U.S. (United States), Columbia, Brazil, and other Latin American nations [12–16]. Within the United States specifically, cases have been documented in Alabama, California, Florida, Georgia, Hawaii, Idaho, Michigan, Montana, New Mexico, North Carolina, Oregon, Rhode Island, South Carolina, Utah, Washington [7,17–20]. A map depicted in Fig. 2 displays these states.

While a previous case was accounted for in the state of South Carolina by Lockhart et. al. in a CDC (Centers for Disease Control) report, this is the first case report documenting C. gattii infection in South Carolina to date. We present a case of Cryptococcus gattii meningitis in a non-HIV/AIDS and non-transplant patient in the state of South Carolina [7].

Case report

A 43-year-old male patient with a recent history of multiple recurrent pneumonias initially presented to the emergency department with a chief complaint of persistent headache and blurry vision. His past medical history included COPD, GERD, hemochromatosis, and lupus. The headache was described as being frontal initially and then becoming retroorbital bilaterally while gradually spreading throughout his head. He reported intermittent photophobia, but denied fever, chills, nausea, and vomiting. No focal neurological deficits were present and no signs of meningismus were detected. However, he was found to have a subacute case of cryptococcal meningitis at that time. Following this finding, treatment with 800 mg fluconazole daily was initiated and he was deemed safe to return home. He was discharged with a combination of hydrocortone-acetaminophen, promethazine, and dexamethasone to manage his nausea and headaches after treatments with 100% oxygen and sumatriptan failed to yield improvement.

After multiple repeat visits to the emergency department for chronic headache and intractable nausea/vomiting as well as reported confusion and word-finding difficulty, neurology was consulted, and imaging of the head was ordered. CT revealed asymmetric effacement of occipital sulci, while MRI revealed multiple non-specific lesions, and diffuse leptomeningeal enhancement (Fig. 1).

Initial vitals revealed that the patient was afebrile and tachycardic, with no electrolyte abnormalities on initial labs. Lumbar puncture performed on the day of admission revealed opening pressure 32 cm, closing pressure 17 cm, white blood cell count of 12, red blood cell count of 427, glucose 4, and protein 137. Cryptococcal antigen was also positive, and titers were >1:2560. On CBC, his white blood cell count was 5.3, with 44.8% neutrophils and 40.8% lymphocytes. CD4 count from previous hospitalization was 559. Immunological workup revealed normal levels of Immunoglobulin A, Immunoglobulin E, Immunoglobulin G, and Immunoglobulin M. Further, the patient was HIV negative and had a negative RPR (Rapid Plasma Reagin). Imaging of the chest taken revealed multiple opacities consistent with pneumonia.

Given his high intracranial pressure, neurosurgery was consulted on initial admission and serial lumbar punctures were recommended to prevent further elevation of pressure.

On Day 2 of admission, fluconazole was discontinued and therapy with 5 mg/kg of amphotericin B QD and 2 g fluocytosine q6hours was initiated. A lumbar drain was also placed by interventional radiology.

On Day 4 of admission, follow-up revealed opening pressure 22 cm (initial was 32 cm) and repeat cerebrospinal fluid cell count drawn from the lumbar drain revealed white blood cell count 107, red blood cell count 5, glucose 82, and protein 104.9. The lumbar drain was removed on hospital day 8 and the patient was monitored for 4 days before discharge on hospital day 12.

On discharge, amphotericin B and fluconazole were prescribed for 42 days pending further evaluation on follow-up [21]. At 2-week follow-up, the Infectious Disease physician recommended readmission to the hospital, which the patient refused. In lieu of admission, outpatient treatment was initiated with amphotericin B 5 mg/kg (milligrams/kilogram) daily, and fluconazole 800 mg daily. On 1-month follow-up, the patient’s therapy was de-escalated to fluconazole 800 mg daily and his symptoms had not progressed further.

![Image 1: CT Head with Contrast](image1.png)

![Image 2: MRI Brain T2 Flair](image2.png)

**Fig. 1.** This figure contains CT and MRI imaging of the patient’s head, showing leptomeningeal enhancement consistent with meningitis and nonspecific lesions.
Discussion

Treatment and expectations

*C. gattii* is a pathogen that is not new to the United States, with over 200 cases documented in the Pacific Northwest, but is unusual in the southeastern United States [12]. With the first reported case of *C. gattii* in the southeastern United States being in 2009, and less than 20 such cases being reported in the region in total, it is a rare infection for the region [7].

In a patient with no history of HIV/AIDS or organ transplant, a number of other factors should be considered. The patient had a chronic cough and had been on steroids multiple times over the months preceding his admission. The combination of steroids, past medical history of Lupus, and likely diminished function of the mucociliary elevator may have also played a role in the patient’s infection.

Based on previous statistical analysis of other cases, time from initial presentation to diagnosis averages 45 days [22]. In this case, diagnosis of a Cryptococcal agent was made after 10 days; however, the diagnosis was changed from the assumed diagnosis of *C. neoformans* after *C. gattii* was grown on culture day 18. This did not impact the patient’s treatment as therapy was initiated 10 days after initial presentation with a headache. Headache is the most common presenting symptom in *C. gattii* infection with 67% of patients, including the patient in this case, having a chief complaint of headache on admission. Choices for induction therapy (the treatment used during the first 2 weeks) consist of a combination of amphotericin B, flucytosine, and fluconazole, with 74% of patients being treated with the most aggressive combination of amphotericin B and flucytosine [11,22]. In the event of increased intracranial pressure from meningoencephalitis, high dose dexamethasone can be given to reduce the inflammatory response and decrease intracranial pressure [23]. In the case of this patient, high dose dexamethasone was given due to concerns about increased intracranial pressure. Consistent with the majority of cases, this patient was also initially treated amphotericin B and flucytosine for the first 2 weeks after diagnosis. While the patient had no HIV/AIDS or history of organ transplant, he was being treated with steroids due to chronic cough as a result of previous pneumonia. Fourteen percent of patients diagnosed with *C. gattii* meningitis were on corticosteroids at the time of diagnosis or were being treated with another immunosuppressive therapy, making a connection in this case plausible [22].

Fig. 2. The figure displays a map of the United States with states having documented cases of *C. gattii* colored red with other states colored gray. Map created using Adobe Illustrator. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
Possible new development in endemicity

Of interest is the patient's denial of recent travel outside the southeastern United States, since previously, most documented cases in the region entailed a connection with California or the Pacific Northwest [20]. Given that the Pacific Northwest has seen the paramount cases of in the U.S., the mode of transmission to this patient raises questions about the communicability of this disease, particularly given the other states in which C. gattii infection has been documented. There has been documentation of multiple cases in which other patients with C. gattii in the southeastern United States have had no contact with regions considered to be endemic such as the Pacific Northwest or Oceana [24]. This case combined with previous cases lends further support to the hypothesis that C. gattii is endemic the southeastern United States (Fig. 2) [24].

Evidence for steroid use as treatment

One randomized, double-blind, control study on the treatment of patients with HIV/AIDS associated cryptococcal meningitis demonstrated that treatment with steroids in these patients was harmful [25]. Of note is the immunocompromised status of these patients and the lack of generalizability to an immunocompetent population. Given the inflammation that follows central nervous system infections, it has been suggested that the use of steroids, particularly after clearance of infection has occurred, may be beneficial [26]. Currently, the ongoing study “Cryptococcus Infection Network in Non-Human Immunodeficiency Virus Cohort (CINCH)” has released preliminary results that indicate positive outcomes in immunocompetent patients treated with steroids relative to those treated without [26,27]. Another study reviewed the outcomes of 4 immunocompetent patients treated with dexamethasone and determined that 3 of 4 had positive outcomes [28]. Although some evidence for steroid use in non-HIV/AIDS and populations exists, the current paucity of conclusive studies on patients without and the contraindication in patients with HIV/AIDS guided the clinical decision to avoid steroids. This patient’s initial subacute course and subsequent chronic infection treated with long term fluconazole provide an example of successful chronic treatment without the long-term use of steroids.

Conclusion

With over 1,000,000 cases and 600,000 deaths estimated due to cryptococcosis worldwide, the global burden of Cryptococcus is significant [2]. Thus, understanding this pathogen is critical from both a worldwide standpoint and from the standpoint of public health in the United States, where it is C. gattii is considered to be endemic to at least the Pacific Northwest [20]. Given that this is the first case report to describe infection with this pathogen in the state of South Carolina, it is important for the infectious disease community within the state and the region to consider C. gattii as an emerging pathogen that may now be endemic to the southeastern United States. The patient described in this case report remained positive for the antigen for at least 4 months after his initial diagnosis. Although neurological cryptococcosis can result in rapid increases in intracranial pressure, the patient continued to only complain of headaches in the outpatient setting that did not increase in severity. With regard to the use of steroids in cryptococcal meningitis, there is a paucity of published data on the use of steroids in the treatment in patients without HIV/AIDS or organ transplant and thus steroids were avoided. This case gives anecdotal evidence for the use of treatments currently supported by literature and for avoidance of dexamethasone until evidence for its use in non-HIV/AIDS and non-transplant populations is put forward.

Sources of funding for your research

Prisma Health Upstate Department of Internal Medicine.

Consent

Yes.

Ethical approval

Yes.

Author contribution

Robert P Summers- writing.

William F Abel- contributed equally in writing.

William S Sessions M.D., M.B.A.-expertise and editing in the field of Internal Medicine.

Eric M Polley M.D.- expertise and editing in the field of Infectious Diseases.

Rhett M Shirley M.D.- expertise and editing in the field of Infectious Diseases.

Amanda E Schnee M.D.- expertise and editing in the field of Infectious Diseases.

Declaration ofCompeting Interest

The authors report no declarations of interest.

References

[1] Chen SC-, Meyer W, Sorrell TC. Cryptococcus gattii infections. Clin Microbiol Rev 2014;27(4):980–1024, doi:http://dx.doi.org/10.1128/CMR.00126-13.

[2] Park BJ, Wannemuehler KA, Marcson R, Goyer DC, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (London, England) 2009;23(4):525–30, doi:http://dx.doi.org/10.1097/QAD.0b013e3283228f1c.

[3] Idrum A, Lin X, Rising to the challenge of multiple cryptococcus species and the diseases they cause. Fungal Genet Biol: FG & B 2015;78:1–6, doi:http://dx.doi.org/10.1016/j.fgb.2015.05.002.

[4] Chong HS, Dagg R, Malik R, Chen S, Carter D. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype. J Clin Microbiol 2010;48(11):4115–20, doi:http://dx.doi.org/10.1128/JCM.01271-10.

[5] Clancy SA, Ciccone EJ, Coelho MA. Cryptococcus deuterogattii VGIa infection associated with travel to the pacific northwest outbreak region in an anti-granulocyte-macrophage colony-stimulating factor autoantibody-positive patient in the united states. Clin Sci Epidemiol 2019:10(1).

[6] Fernandes KE, Dwyer C, Campbell LT, Carter DA. Species in the cryptococcus gattii complex differ in capsule and cell size following growth under capsule-inducing conditions. Mophere 2016;1(6), doi:http://dx.doi.org/10.1128/mSphere.00350-16.

[7] Lockhart SR, Iqbal N, Harris JR, Grossman NT, DeBess E, Wohrle R, et al. Cryptococcus gattii in the united states: genotypic diversity of human and veterinary isolates. PLoS One 2013;8(9):e74737, doi:http://dx.doi.org/10.1371/journal.pone.0074737.

[8] May RC, Stone NRH, Wiesner DL, Bicanic T, Nielsen K. Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol 2016;14(2):106–17, doi:http://dx.doi.org/10.1038/nrmmicro.2015.6.

[9] Ruma-Haynes P, Brownlee AG, Sorrell TC. A rapid method for detecting extracellular proteinase activity in cryptococcus neoformans and a survey of 63 isolates. J Med Microbiol 2000;49(8):733–7 Retrieved from EBSCOhost; mnh database.

[10] Perfect JR, Dismukes WE, Drome F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010;50(3):291–322, doi:http://dx.doi.org/10.1086/649858.

[11] Desalegnos A, Kourkoumpetis T, Mylonakis E. Update on the epidemiology and management of cryptococcal meningitis. Expert Opin Pharmacother 2013;13(6):783–9, doi:http://dx.doi.org/10.1517/14656566.2012.658773.
[12] Galanis E, Macdougall I, Kidd S, Morshed M. Epidemiology of cryptococcus gattii, british colombia, canada, 1999–2007. Emerging Infect Dis 2010;16 (2):251–7, doi:http://dx.doi.org/10.3201/eid1602.090900.

[13] Sukroongreung S, Nilakul C, Ruangsomboon G, Chuakul W, Eamphokalap B. Serotypes of cryptococcus neoformans isolated from patients prior to and during the AIDS era in thailand. Mycopathologia 1996;135(2):75–8 Retrieved from EBSCOhost; mnh database.

[14] Fisher D, Burrow J, Lo D, Currie B. Cryptococcus neoformans in tropical northern australia: Predominantly variant gattii with good outcomes. Aust NZ J Med 1993;23(6):678–82 Retrieved from EBSCOhost; mnh database.

[15] Seaton RA. The management of cryptococcal meningitis in papua new guinea. P N C Med J 1996;39:167–73 Retrieved from EBSCOhost; mnh database.

[16] Ficaraticová C, Lizaroz J, Illnait-Zaragozá MT, Castañe eda E. The status of cryptococcus in latin america. Mem Inst Oswaldo Cruz 2018;113(7):e170554, doi:http://dx.doi.org/10.1590/0071-8549.2018.113.7.e170554.

[17] Harris JR, Lockhart SR, Sondemeyer G, Yuga DJ, Crist MB, D’Angelo MT, et al. Cryptococcus gattii infections in multiple states outside the US pacific northwest. Emerging Infect Dis 2013;19(10):1620–6, doi:http://dx.doi.org/10.3201/eid1910.130441.

[18] Upton A, Fraser JA, Kidd SE, Bretz C, Bartlett KH, Heitman J, et al. First contemporary case of human infection with cryptococcus gattii in puget sound: Evidence for spread of the vancouver island outbreak. J Clin Microbiol 2007;45(9):3086–8 Retrieved from EBSCOhost; mnh database.

[19] Kidd SE, Chow Y, Mak S, Bach PJ, Chen H, Hingston AO, et al. Characterization of environmental sources of the human and animal pathogen cryptococcus gattii in british colombia, canada, and the pacific northwest of the united states. Appl Environ Microbiol 2007;73(5):1431–43 Retrieved from EBSCOhost; mnh database.

[20] Byrnes EJ, Li W, Lewit Y, Perfect JR, Carter DA, Cox GM, et al. First reported case of cryptococcus gattii in the southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS One 2009;4(6):e5851, doi:http://dx.doi.org/10.1371/journal.pone.0005851.

[21] Chen SC-, Korman TM, Slavin MA, Marriott D, Byth K, Bak N, et al. Antifungal therapy and management of complications of Cryptococcus due to Cryptococcus gattii. Clin Infect Dis 2013;57(4):543–51, doi:http://dx.doi.org/10.1093/cid/cit341.

[22] Chen SC-, Slavin MA, Heath CH, Playford EG, Byth K, Marriott D, et al. Clinical manifestations of cryptococcus gattii infection: Determinants of neurological sequelae and death. Clin Infect Dis 2012;55(6):789–98 Retrieved from EBSCOhost; mnh database.

[23] Amburgy JW, Miller JJH, Ditty BJ, Vande Lune P, Muhammad S, et al. Cryptococcus gattii in an immunocompetent patient in the Southeastern United States. Case Rep Infect Dis 2016;2016:8280915, doi:http://dx.doi.org/10.1155/2016/8280915.

[24] Lockhart SR, Roe CC, Engelthaler DM. Whole-genome analysis of cryptococcus gattii, southeastern united states. Emerging Infect Dis 2016;22(6):1098–101, doi:http://dx.doi.org/10.3201/eid2206.151455.

[25] Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, Cuc NT, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med 2016;374(6):542–54, doi:http://dx.doi.org/10.1056/NEJMoa1509024.

[26] Panackal AA, Marr KA, Williamson PR. Dexamethasone in cryptococcal meningitis. N Engl J Med 2016;375(2):188, doi:http://dx.doi.org/10.1056/ NEJMc1605205.

[27] Phillips P, Chapman K, Sharp M, Harrison P, Vortel J, Steiner T, et al. Dexamethasone in cryptococcus gattii central nervous system infection. Clin Infect Dis 2009;49(4):591–5, doi:http://dx.doi.org/10.1086/603354.

[28] Spec A, Panackal A, Williamson P, Bennett JE, Garcia-Diaz J, Ostrander D, et al. Cryptococcus infection network in non-human immunodeficiency virus cohort (CINCH): study: initial report of treatment and outcomes. Open Forum Infect Dis 2016;3(1):122.